NICE guidance on inclisiran should be reconsidered

BMJ. 2021 Oct 12:375:n2462. doi: 10.1136/bmj.n2462.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Anticholesteremic Agents / economics*
  • Anticholesteremic Agents / pharmacology
  • Clinical Trials, Phase III as Topic
  • Heart Disease Risk Factors
  • Humans
  • Lipoproteins, LDL / drug effects
  • RNA, Small Interfering / economics*
  • RNA, Small Interfering / pharmacology

Substances

  • ALN-PCS
  • Anticholesteremic Agents
  • Lipoproteins, LDL
  • RNA, Small Interfering